DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage

DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage

Oncolytic virotherapy is a promising strategy for cancer treatment. In this study, the authors demonstrate that DNA-dependent protein kinase (DNA-PK) inhibition sensitizes cancer cells to M1 virus and improves therapeutic effects in refractory cancer models in vivo and in patient tumour samples.

Guardado en:
Detalles Bibliográficos
Autores principales: Xiao Xiao, Jiankai Liang, Chunlong Huang, Kai Li, Fan Xing, Wenbo Zhu, Ziqing Lin, Wencang Xu, Guangen Wu, Jifu Zhang, Xi Lin, Yaqian Tan, Jing Cai, Jun Hu, Xueqin Chen, Youwei Huang, Zixi Qin, Pengxin Qiu, Xingwen Su, Lijun Chen, Yuan Lin, Haipeng Zhang, Guangmei Yan
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/dbf1917a6c734ba89788a062a0d2b470
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Oncolytic virotherapy is a promising strategy for cancer treatment. In this study, the authors demonstrate that DNA-dependent protein kinase (DNA-PK) inhibition sensitizes cancer cells to M1 virus and improves therapeutic effects in refractory cancer models in vivo and in patient tumour samples.

Ejemplares similares